-->

Tag: CD19-targeted CAR-T

Home / CD19-targeted CAR-T

Categories

Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma

May 2024: The Food and Drug Administration has granted approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory mantle c...
cd19-targeted-car-t

Lisocabtagene maraleucel is granted accelerated approval by FDA for follicular lymphoma

May 2015:  Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been granted rapid approval by the Food and Drug Administration. This approval is specifically for people with relapsed or ...
cd19-targeted-car-t

Scan the code